Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. McMillan Shakespeare Limited
  6. News
  7. Summary
    MMS   AU000000MMS5

MCMILLAN SHAKESPEARE LIMITED

(MMS)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

McMillan Shakespeare Limited Announces Board Changes

10/06/2020 | 02:04am EDT

McMillan Shakespeare Limited announced that Helen Kurincic will succeed Tim Poole as the Company's Chair at the conclusion of the upcoming Annual General Meeting on 20 October 2020. Tim will continue as a Non-Executive Director until October 2021. Helen joined the MMS Board in September 2018. She has deep senior executive and Board experience across the healthcare and related sectors. Helen is currently the Non-Executive Chair of Integral Diagnostics Limited, and a non-executive director of Estia Health Limited, HBF Health Limited and Victorian Clinical Genetics Services. Prior to taking on several Board roles, Helen was the Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first and radiation oncology and cardiology business across Australia.


© S&P Capital IQ 2020
All news about MCMILLAN SHAKESPEARE LIMITED
09/09MCMILLAN SHAKESPEARE LIMITED : Ex-dividend day for final dividend
FA
08/24McMillan Shakespeare Limited acquired Plan Tracker.
CI
08/23McMillan Shakespeare Limited Declares Dividend for the Six Months Ended June ..
CI
08/23Mcmillan Shakespeare Limited Reports Earnings Results for the Full Year Ended..
CI
08/23McMillan Shakespeare Limited Declares A Final Dividend, Payable on 24 Septemb..
CI
06/10McMillan Shakespeare Limited Announces Executive Changes
CI
04/13Mcmillan Shakespeare Limited Announces the Appointment of Bruce Akhurst as Di..
CI
03/30Mcmillan Shakespeare Limited Announces Board Changes with Effect from 1 April..
CI
03/11MCMILLAN SHAKESPEARE LIMITED : Ex-dividend day for interim dividend
FA
02/24McMillan Shakespeare Limited acquired remaining 50% stake in Maxxia Limited f..
CI
More news
Financials
Sales 2022 554 M 402 M 402 M
Net income 2022 81,6 M 59,2 M 59,2 M
Net Debt 2022 27,2 M 19,8 M 19,8 M
P/E ratio 2022 12,4x
Yield 2022 4,96%
Capitalization 1 006 M 732 M 730 M
EV / Sales 2022 1,86x
EV / Sales 2023 1,78x
Nbr of Employees -
Free-Float 81,1%
Chart MCMILLAN SHAKESPEARE LIMITED
Duration : Period :
McMillan Shakespeare Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCMILLAN SHAKESPEARE LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 13,00 AUD
Average target price 14,70 AUD
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
Michael Neil Salisbury Chief Executive Officer, MD & Executive Director
Ashley Conn Chief Financial Officer & Secretary
Helen Kurincic Chairman
Kathy Parsons Independent Non-Executive Director
Bruce J. Akhurst Independent Non-Executive Director